Researchers at Weill Cornell Medicine have developed a library of 220 patient-derived tumor organoids and a new method for creating immunocompetent lung tumor organoids. These advancements provide researchers with scalable, long-term preclinical models to test cancer treatments, potentially allowing for more personalized drug selection and improved clinical trial outcomes.
Building a 220-Organoid Library for Precision Oncology
Investigators at the Englander Institute for Precision Medicine at Weill Cornell Medicine have significantly expanded the toolkit available for cancer researchers. In a study published June 26 in Science Advances, the team introduced a library of 220 tumor organoids derived from 190 patients. These three-dimensional cell clusters represent 15 different types of cancer, providing a versatile platform for studying how tumors respond to various therapies.
The research team performed extensive characterization of these models, confirming that the organoids maintain high stability and similarity to the original tumors in terms of driver DNA mutations and gene expression patterns. This fidelity is essential for researchers who rely on these models to predict how a patient’s specific cancer might react to a drug.
Testing PARP Inhibitors Beyond Current Clinical Criteria
One of the primary advantages of this new library is its ability to challenge existing treatment paradigms. According to WCM Newsroom, researchers used the organoids to test the effectiveness of talazoparib, a PARP inhibitor, on tumor samples that standard clinical criteria had previously deemed ineligible for such treatment.
The results were striking: more than half, or 58%, of the tested organoids showed substantial sensitivity to the drug. This finding suggests that current clinical guidelines may be excluding a significant number of patients who could actually benefit from PARP inhibitors. By analyzing the mutational features that made these organoids susceptible, the team aims to provide a clearer path for expanding clinical eligibility criteria.
“Essentially, these organoids appear to be very good preclinical models of the parent tumor, and are practical models because they can be used long-term.”
Dr. Andrea Sboner, associate professor of pathology and laboratory medicine at Weill Cornell
Recapitulating the Tumor Immune Microenvironment
Beyond drug sensitivity, the team addressed a long-standing hurdle in cancer research: the difficulty of replicating a tumor’s immune environment. Incorporating immune components like T cells is vital because they play a central role in how a patient responds to immunotherapy, particularly checkpoint inhibitors.
In a separate study published May 13 in Cell Reports Methods, the Weill Cornell investigators successfully developed lung tumor organoids that include these essential immune elements. These models allow for high-throughput testing, enabling researchers to rapidly evaluate T cell activity under various treatment regimens.
“All of the assays we developed for these ‘immunocompetent’ organoids are scalable for high-throughput testing, which highlights the promise of these models for precision medicine.”
Dr. M. Laura Martin, senior author and director of the tumor organoid platform in the Englander Institute at Weill Cornell Medicine at the time the research was performed
The Future of Patient Avatars in Clinical Trials
The researchers view these organoids as more than just lab tools; they are potential “avatars” that could revolutionize the clinical trial process. By using a patient’s own tumor cells to model treatment responses, clinicians may eventually be able to gain an early look at both the therapeutic efficacy and potential side effects of experimental drugs before they are administered to the patient.
While the prospect of using tumor avatars in routine clinical practice may currently feel like a concept from a science fiction novel, the research team suggests that this reality is closer than many might expect. As the field moves forward, the primary question remains how quickly these scalable, high-throughput screening methods can be integrated into standard oncology workflows to improve real-world patient outcomes.
“You can use these organoids as patient ‘avatars’ during clinical trials of experimental therapies, for example, to get an early picture of treatment effects and side effects,”
Dr. Juan Miguel Mosquera, professor of pathology and laboratory medicine and director of research pathology at the Englander Institute
Related reading
